PMID- 22814142
OWN - NLM
STAT- MEDLINE
DCOM- 20130509
LR  - 20220409
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 59
IP  - 11
DP  - 2012
TI  - Long term effects of the implantation of autologous bone marrow mononuclear cells 
      for type 2 diabetes mellitus.
PG  - 1031-9
AB  - Previous studies have shown that several types of stem cells can differentiate 
      into insulin-secreting islet beta-cells and that these cells can reduce blood 
      glucose in some trials, but there has been no report of a long-term follow-up. We 
      assessed the long-term effects of the use of autologous bone marrow mononuclear 
      cells in the treatment of type 2 diabetes mellitus (T2DM). Based on the 
      willingness to receive implantation of bone marrow mononuclear cells, One hundred 
      and eighteen patients with T2DM were divided into two groups; the patients in 
      group I were treated with autologous bone marrow mononuclear cells and patients 
      in group II were treated with insulin intensification therapy. Mononuclear cells 
      from bone marrow were injected back into the patient's pancreas via a catheter. 
      Patients were followed-up after the operation at monthly intervals for the first 
      3 months and thereafter every 3 months for the next 33 months, the occurrence of 
      any side effects and the results of laboratory examinations were evaluated. There 
      were no reported acute or chronic side effects in group I and both the HbA1c and 
      C-peptide in group I patients were significantly better than either pretherapy 
      values or group II patients during the follow-up period. These data suggested 
      that the implantation of autologous bone marrow mononuclear cells for the 
      treatment of T2DM is safe and effective. This therapy can partially restore the 
      function of islet beta-cells and maintain blood glucose homeostasis in a longer 
      time.
FAU - Hu, Jianxia
AU  - Hu J
AD  - Stem Cell Research Center, the Affiliated Hospital of Medical College, Qingdao 
      University, Qingdao 266003, China.
FAU - Li, Chengqian
AU  - Li C
FAU - Wang, Li
AU  - Wang L
FAU - Zhang, Xuefeng
AU  - Zhang X
FAU - Zhang, Meirong
AU  - Zhang M
FAU - Gao, Hong
AU  - Gao H
FAU - Yu, Xiaolong
AU  - Yu X
FAU - Wang, Fang
AU  - Wang F
FAU - Zhao, Wenjuan
AU  - Zhao W
FAU - Yan, Shengli
AU  - Yan S
FAU - Wang, Yangang
AU  - Wang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120713
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Insulin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bone Marrow Cells/cytology
MH  - *Bone Marrow Transplantation/methods
MH  - Cell Differentiation
MH  - Diabetes Mellitus, Type 2/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Insulin/therapeutic use
MH  - Insulin-Secreting Cells/cytology
MH  - Male
MH  - Middle Aged
MH  - Transplantation, Autologous
EDAT- 2012/07/21 06:00
MHDA- 2013/05/10 06:00
CRDT- 2012/07/21 06:00
PHST- 2012/07/21 06:00 [entrez]
PHST- 2012/07/21 06:00 [pubmed]
PHST- 2013/05/10 06:00 [medline]
AID - DN/JST.JSTAGE/endocrj/EJ12-0092 [pii]
AID - 10.1507/endocrj.ej12-0092 [doi]
PST - ppublish
SO  - Endocr J. 2012;59(11):1031-9. doi: 10.1507/endocrj.ej12-0092. Epub 2012 Jul 13.